Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Short Interest Up 74.2% in March

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) was the recipient of a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 51,400 shares, a growth of 74.2% from the February 28th total of 29,500 shares. Approximately 4.1% of the shares of the company are sold short. Based on an average daily trading volume, of 51,600 shares, the days-to-cover ratio is presently 1.0 days.

Cadrenal Therapeutics Price Performance

Shares of CVKD traded down $0.25 during mid-day trading on Friday, reaching $18.46. 9,884 shares of the company’s stock were exchanged, compared to its average volume of 39,807. The business’s fifty day simple moving average is $18.79 and its 200-day simple moving average is $15.89. Cadrenal Therapeutics has a 52-week low of $5.40 and a 52-week high of $22.90. The stock has a market capitalization of $34.70 million, a PE ratio of -2.76 and a beta of 1.40.

Cadrenal Therapeutics (NASDAQ:CVKD) last posted its quarterly earnings data on Thursday, March 13th. The company reported ($2.74) EPS for the quarter, missing analysts’ consensus estimates of ($1.71) by ($1.03). Equities research analysts predict that Cadrenal Therapeutics will post -7.59 earnings per share for the current year.

Institutional Trading of Cadrenal Therapeutics

An institutional investor recently bought a new position in Cadrenal Therapeutics stock. Geode Capital Management LLC acquired a new stake in Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 10,554 shares of the company’s stock, valued at approximately $153,000. Geode Capital Management LLC owned about 0.59% of Cadrenal Therapeutics at the end of the most recent reporting period. Institutional investors own 7.92% of the company’s stock.

Cadrenal Therapeutics Company Profile

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.